300 related articles for article (PubMed ID: 33837465)
1. Pharmacological Activation of Neuronal Voltage-Gated Kv7/KCNQ/M-Channels for Potential Therapy of Epilepsy and Pain.
Liu Y; Bian X; Wang K
Handb Exp Pharmacol; 2021; 267():231-251. PubMed ID: 33837465
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of neuronal KCNQ channel modulators.
Gribkoff VK
Expert Opin Ther Targets; 2003 Dec; 7(6):737-48. PubMed ID: 14640909
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
[TBL] [Abstract][Full Text] [Related]
5. Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Xu W; Wu Y; Bi Y; Tan L; Gan Y; Wang K
Mol Pain; 2010 Aug; 6():49. PubMed ID: 20796319
[TBL] [Abstract][Full Text] [Related]
6. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
7. Neural KCNQ (Kv7) channels.
Brown DA; Passmore GM
Br J Pharmacol; 2009 Apr; 156(8):1185-95. PubMed ID: 19298256
[TBL] [Abstract][Full Text] [Related]
8. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.
Varghese N; Lauritano A; Taglialatela M; Tzingounis AV
J Neurophysiol; 2021 Apr; 125(4):1440-1449. PubMed ID: 33729829
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
10. Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain.
Wang J; Liu Y; Hu F; Yang J; Guo X; Hou X; Ju C; Wang K
J Pharmacol Exp Ther; 2021 Apr; 377(1):20-28. PubMed ID: 33431609
[TBL] [Abstract][Full Text] [Related]
11. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
12. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
13. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
14. Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy.
Zahra A; Liu R; Wang J; Wu J
Neurol Sci; 2023 Nov; 44(11):3819-3825. PubMed ID: 37442907
[TBL] [Abstract][Full Text] [Related]
15. Peripheral K
Peiris M; Hockley JR; Reed DE; Smith ESJ; Bulmer DC; Blackshaw LA
Mol Pain; 2017; 13():1744806917709371. PubMed ID: 28566000
[TBL] [Abstract][Full Text] [Related]
16. Novel K
Seefeld MA; Lin H; Holenz J; Downie D; Donovan B; Fu T; Pasikanti K; Zhen W; Cato M; Chaudhary KW; Brady P; Bakshi T; Morrow D; Rajagopal S; Samanta SK; Madhyastha N; Kuppusamy BM; Dougherty RW; Bhamidipati R; Mohd Z; Higgins GA; Chapman M; Rouget C; Lluel P; Matsuoka Y
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3793-3797. PubMed ID: 30327146
[TBL] [Abstract][Full Text] [Related]
17. Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant.
Krüger J; Lerche H
Neuropharmacology; 2024 Jun; 250():109892. PubMed ID: 38428481
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of Lu AA41178: A novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders.
Grupe M; Bentzen BH; Benned-Jensen T; Nielsen V; Frederiksen K; Jensen HS; Jacobsen AM; Skibsbye L; Sams AG; Grunnet M; Rottländer M; Bastlund JF
Eur J Pharmacol; 2020 Nov; 887():173440. PubMed ID: 32745603
[TBL] [Abstract][Full Text] [Related]
19. Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Cooper EC
Epilepsia; 2001; 42 Suppl 5():49-54. PubMed ID: 11887968
[TBL] [Abstract][Full Text] [Related]
20. The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine.
Syeda R; Santos JS; Montal M
J Biol Chem; 2016 Feb; 291(6):2931-7. PubMed ID: 26627826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
